Institutional members access full text with Ovid®

Share this article on:

Effect of Bisphosphonates on Bone Mineral Density and Fracture Prevention in Gastric Cancer Patients After Gastrectomy

Lim, Jung Sub MD, PhD*; Jin, Sung-Ho MD; Kim, Sang Bum MD; Lee, Jong-Inn MD, PhD

Journal of Clinical Gastroenterology: September 2012 - Volume 46 - Issue 8 - p 669–674
doi: 10.1097/MCG.0b013e31824f1af4
ALIMENTARY TRACT: Original Articles

Goal: To evaluate the effectiveness of bisphosphonates in preventing fractures in gastric cancer patients by increasing bone mineral density (BMD).

Background: The effectiveness of bisphosphonates is questionable in gastric cancer patients who have undergone gastrectomy, although they display a high prevalence of osteoporosis.

Study: Forty-seven gastric cancer patients with osteoporosis were retrospectively analyzed. All patients were supplemented with calcium and vitamin D. Twenty-four patients were treated with bisphosphonate (bisphosphonate group) and 23 patients were untreated (control group). Fractures, severe bone pain, and adverse effects of bisphosphonates were monitored. BMD of the lumbar spine and femoral neck were measured before and 1-year treatment with bisphosphonates by dual-energy X-ray absorptiometry.

Results: During a 1-year follow-up, 7 of the 47 (15%) patients developed new fractures. The bisphosphonate-treated group had a significantly lower fracture rate than the control group (n=1 vs. 6, P<0.05). Lumbar spine BMD increased in both groups (0.047±0.03 vs. 0.021±0.03 g/cm2, respectively), whereas femoral neck BMD increased only in the bisphosphonate group (0.032±0.03 vs. −0.004±0.02 g/cm2, respectively). Furthermore, the bisphosphonate group showed greater increases in lumbar spine and femoral neck BMDs than the controls (P<0.05). No difference was found between alendronate and risedronate in terms of BMD at follow-up.

Conclusions: Therapy using bisphosphonates might be effective at increasing BMD and reducing fracture risk in gastric cancer patients after gastrectomy. Further well-designed randomized controlled trials are needed for confirmation.

*Departments of Pediatrics

Surgery, Korea Cancer Central Hospital, Seoul, Republic of Korea

This study was supported by the Clinical Research Fund of the Korean Institute of Radiological and Medical Sciences.

The authors declare that they have nothing to disclose.

Reprints: Jong-Inn Lee, MD, PhD, Department of Surgery, Korea Cancer Center Hospital, Gongneung-dong 215, Nowon-gu, Seoul, Republic of Korea 139-706 (e-mail: jilee@kcch.re.kr).

Received July 31, 2011

Accepted February 7, 2012

© 2012 Lippincott Williams & Wilkins, Inc.